Medical news today: Thursday, November 12, 2026
WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Get tomorrow's issue in your inbox.
- 01
WHO says the Bundibugyo Ebola outbreak remains a public health emergency
Source: World Health Organization
In remarks on 11 November, WHO said the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo remains a public health emergency of international concern, with almost 11,000 confirmed cases and more than 5,300 deaths reported across eight provinces. WHO highlighted more than 1,000 contacts lost to follow-up and three confirmed cases unaccounted for, with insecurity and attacks on health workers and facilities disrupting response operations. WHO also said Kenya had discharged its final patient and begun the 42-day countdown toward Ebola-free status. The briefing noted that vaccine research is continuing, including evaluation of additional Bundibugyo-virus candidates; these remain investigational.
Why it mattersThe update points to major surveillance, contact-tracing and access gaps despite signs of slowing transmission in some areas. Outbreak counts and response constraints should be interpreted in context; candidate-vaccine recommendations are not evidence of established protective efficacy. More on Drug & device safety →
- 02
WHO and the African Medicines Agency advance regional regulatory and pharmacovigilance cooperation
Source: World Health Organization
In a 10 November update about the inaugural African Medicines Agency Week held in Kigali from 25 to 30 October, WHO said the Agency inaugurated seven technical committees covering medicines and vaccines evaluation, clinical-trial oversight, inspections, vigilance and medical devices. WHO reported that 10 African national regulatory authorities have reached Maturity Level 3 under its Global Benchmarking programme. The meeting also saw the launch of regulatory innovation and manufacturing-readiness and capacity-strengthening hubs.
Why it mattersThe initiatives could strengthen regulatory reliance, clinical-trial oversight and pharmacovigilance work-sharing across African countries, supporting access to quality-assured products. This is a capacity-building and governance update, not a new medicine approval or a finding that all national systems have reached the same level. More on Approvals & regulatory →
- 03
FDA approves asundexian, the first factor XIa inhibitor, for selected patients after ischaemic stroke or high-risk TIA
Source: U.S. Food and Drug Administration
On 9 November, the FDA approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa inhibitor, for use with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack. In the phase 3 OCEANIC-STROKE trial, which enrolled 12,327 adults, asundexian reduced ischaemic stroke risk by 26% versus placebo over a median treatment period of 14.2 months. Overall major bleeding rates were similar, but bleeding was increased in patients older than 75 and during the first 90 days; gastrointestinal bleeding was more common. The drug is not approved for stroke prevention in atrial fibrillation.
Why it mattersThis is a U.S. regulatory approval for a defined secondary-prevention population. Clinical and PV teams should note the required antiplatelet background therapy, age- and time-related bleeding findings, drug-interaction cautions and the explicit exclusion of atrial-fibrillation-related stroke. More on Approvals & regulatory →
- 04
WHO seeks feedback on specifications for wearables used in population physical-activity surveillance
Source: World Health Organization
WHO opened a consultation on 8 November, running until 6 December 2026, on a draft target product profile for wrist-worn wearables intended to measure physical activity and sedentary behaviour in national and subnational population-health monitoring systems. The draft sets out minimum and enhanced device specifications and considers data access, implementation and operational deployment. WHO is seeking feedback on technical feasibility and applicability across different country contexts, particularly low- and middle-income settings.
Why it mattersThe profile could help public-health agencies and developers converge on fit-for-purpose devices and more comparable surveillance data. It remains a draft for consultation, not a device approval, clinical guideline or endorsement of a particular commercial wearable. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Wednesday, November 11, 2026FDA approves pimicotinib; GLP-1 eye warning and two device alerts; WHO updates TB resistance catalogue
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
